ADVA
12.9.2019 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has been selected as the strategic technology partner of Sify Technologies Limited. Sify, the largest ICT service provider in India, is deploying the ADVA FSP 150 as the foundation of its new managed Ethernet service offering. The intelligent, multi-layer demarcation and aggregation technology will enable Sify to deliver secure, highly reliable end-to-end Ethernet services, leveraging its nationwide MPLS core network. The offering completes Sify’s ICT solution suite and empowers its end users to streamline operations, cut costs and rapidly seize new business opportunities. In addition to providing intelligent managed enterprise services, Sify will use the ADVA technology to extend its wholesale service footprint, giving more international carriers access to the Indian subcontinent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190912005040/en/
“Our new managed Ethernet offering fills the final gap in our portfolio. With ADVA as our technology partner, we can roll out high-capacity Layer 2 services with total flexibility and bring intelligence and automation to the edge of our enterprise network,” said Harsha Ram, VP, telecom services, Sify. ”The ADVA FSP 150 delivers new levels of agility for service innovation. It empowers us to provide the ideal solution for the budget, strategy and technical needs of each and every customer. What’s more, with ADVA’s technology, we can put IP traffic control at the end user’s fingertips. With incredible speed and efficiency, customers can take charge of their services, managing IP addresses and altering IP routing without restriction.”
With more than 10,000 enterprise customers across the Indian subcontinent, Sify has seen an enormous increase in data demand. The ADVA FSP 150 is the ultimate response. Deployed at the customer premises, the ADVA FSP 150 demarcation solution delivers MEF-certified CE 2.0 services and provides several key advantages. It’s highly interoperable, enabling seamless integration with Sify’s existing network management system. With its comprehensive set of service assurance functions, the solution offers full visibility of service quality – an essential tool for effective SLA management. The device also provides the flexibility to quickly transition from 1Gbit/s to 10Gbit/s Ethernet services without requiring extra space and power consumption.
“Our FSP 150 technology has always been at the forefront of Ethernet access innovation. Now we’re using all of our experience as a global leader with an enormous installed base to bring scalable, SLA-assured business and cloud access to Sify’s customers. With our multi-technology platform, Sify will be able to reduce costs and significantly simplify operations,” commented Sivakumar Krishna Iyer, director, global business development, ADVA. “Our FSP 150 provides comprehensive assurance, delivering unparalleled support for SLA management. It also effortlessly expands from 1GbE to 10GbE. What’s more, our solution offers zero-touch provisioning as standard so it can easily be installed and connected by customers with no risk of error. This makes it the ideal technology to enable major operators like Sify to rollout tomorrow’s business connectivity on an enormous scale.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com
.
About Sify Techologies
Sify is the largest ICT service provider, system integrator and all-in-one network solutions company on the Indian subcontinent. We’ve also expanded to the United States, with headquarters in the heart of California’s Silicon Valley. Over 10,000 businesses have become Sify customers. We also partner with other major network operators to deliver global network solutions. Our customers can access Sify services via India’s largest MPLS network. Among the very few enterprise class players in India, Sify, today has presence in more than 1,600 cities in India and in North America, the United Kingdom and Singapore. www.sifytechnologies.com
Published by:
ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005040/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
